Zolucatetide
Parabilis Medicines' stabilized helical peptide and the first direct inhibitor of the β-catenin:TCF protein-protein interaction — a target considered undruggable for thirty years. Updated Phase 1/2 desmoid data presented at ESMO on 24 October 2026 reported a 72.2% (13/18) RECIST 1.1 objective response rate at a 32-week landmark and 100% disease control across 46 response-evaluable patients. The drug holds FDA Fast Track (November 2025) and Orphan Drug (March 2026) designations, and Parabilis has aligned with the FDA on a registrational Phase 3 trial, PEDESTAL, planned to start in the first half of 2027.
Zolucatetide is an experimental cancer drug — a designed peptide given by IV drip — that blocks a protein interaction inside cells which drives desmoid tumors and several other cancers. Nobody had managed to block it with a drug before. In an early-stage trial, tumors shrank in most patients who were treated, and the company has agreed a final-stage trial with the FDA that starts in 2027. It is not approved, and the only way to get it is to join the trial.
What is Zolucatetide?
Zolucatetide (development code FOG-001) is Parabilis Medicines' lead clinical asset and the first direct inhibitor of the β-catenin:TCF protein-protein interaction to reach human trials — a target the oncology field considered undruggable for three decades because the binding interface (~4,800 Ų of flat, hydrophobic surface) is too large for traditional small molecules. The molecule is built on the Helicon platform, a class of polymacrocyclic α-helical peptides engineered to enforce α-helicity, minimize solvent-exposed amide hydrogen-bond donors, and achieve cytosolic exposure adequate for binding intracellular targets. Its WHO INN chemical name describes a 15-residue acetylated peptide rich in non-natural amino acids, braced by three cross-links: an all-hydrocarbon hexenediyl bridge (the classic stapled-peptide chemistry), a carbamate bridge, and a side-chain lactam. Disclosed chemistry: molecular formula C102H134N18O25S2, molecular weight 2,076.4 Da, CAS 3044032-95-0; the starting point was found through the Helicon platform's phage-display screening. Zolucatetide is administered intravenously on a continuous 28-day cycle schedule. Phase 1/2 NCT05919264 (estimated n=619) is enrolling locally advanced or metastatic solid tumors with Wnt-pathway activating mutations, with cohorts in colorectal cancer, hepatocellular carcinoma, desmoid tumors, castration-resistant prostate cancer, and familial adenomatous polyposis (FAP), plus combination cohorts with mFOLFOX-6 + bevacizumab, nivolumab, and trifluridine/tipiracil + bevacizumab. The current desmoid dataset was presented at ESMO Congress 2026 in Madrid on 24 October 2026 (abstract 3715O). As of a 22 June 2026 cutoff, 76 desmoid patients had been enrolled and treated across all dose levels; 48 started at the selected induction dose of 450 mg or higher, of whom 46 were response-evaluable and 18 had reached the 32-week landmark. The objective response rate at that landmark was 72.2% (13/18) by RECIST 1.1, the disease control rate was 100% across all 46 response-evaluable patients, and no disease progression was reported in that cohort. Median time on treatment was 4.7 months (range 0.5–22.3). Responses occurred irrespective of prior gamma-secretase inhibitor (GSI) exposure and regardless of CTNNB1 versus APC mutation status. These figures supersede the earlier February 2026 cut disclosed in the IPO prospectus, which reported 38 patients treated and a 74% (14/19) objective response rate. The FDA granted Fast Track designation for desmoid tumors in November 2025 and Orphan Drug Designation on March 11, 2026. Parabilis closed a $305M Series F in January 2026, signed an antibody-Helicon conjugate collaboration with Regeneron in May 2026, and priced its IPO on June 9, 2026 (Nasdaq: PBLS) at $20 per share, raising $770.5M gross including the over-allotment. Following end-of-Phase-2 discussions, Parabilis has reached alignment with the FDA on the dose, a placebo-controlled design and progression-free survival as the registrational primary endpoint. The resulting Phase 3 trial, PEDESTAL (Phase 3 Evaluation of DESmoid Tumor Activity with zoLucatetide), is randomized, double-blind and placebo-controlled, is planned to start in the first half of 2027, and is expected to report topline results in 2029.
What Zolucatetide Is Investigated For
Zolucatetide is the clinical proof-of-concept for an undruggable target: the β-catenin:TCF protein-protein interaction that sits at the transcriptional output of the Wnt signaling pathway. Wnt-pathway dysregulation drives desmoid tumors (~85% CTNNB1-mutated, ~10–15% FAP-associated APC-loss), most colorectal cancers, hepatocellular carcinoma subsets, and Wnt-mutant endometrial and prostate cancers — collectively a large slice of the oncology landscape. Prior pharmacological approaches all targeted the pathway upstream of β-catenin nuclear function: tankyrase inhibitors (XAV939, AZ1366), porcupine inhibitors (LGK974/WNT974, ETC-159, CGX1321), and the indirect approach exemplified by nirogacestat (Ogsiveo), an oral γ-secretase inhibitor that became the first FDA-approved desmoid therapy in November 2023 with a 41% RECIST 1.1 ORR in the pivotal DeFi trial, rising to 45.7% with up to four years of treatment (J Clin Oncol 2025). A second γ-secretase inhibitor, Immunome's varegacestat, reported a 56% versus 9% ORR in the 156-patient RINGSIDE Phase 3 and has an FDA decision date of April 28, 2027. Zolucatetide is the first molecule to directly engage the β-catenin:TCF interaction itself, and its 72.2% landmark ORR sits above both — but the comparison is cross-trial. Honest caveats are substantial. The 72.2% comes from an open-label Phase 1/2 with a small denominator (13 of 18 patients who had reached the 32-week landmark as of 22 June 2026), is not randomized, includes both GSI-naive and GSI-failed patients, and has not been peer-reviewed. The 100% disease control rate is the more robust number because its denominator is larger (46 response-evaluable patients), but disease control counts stable disease, and desmoid tumors are slow-growing enough that roughly a quarter to a third of them regress on their own under active surveillance. Median time on treatment was only 4.7 months. The only PubMed-indexed zolucatetide publication remains a 2026 NEJM letter describing a single patient with recurrent ameloblastoma; the desmoid data come from company disclosures and conference presentations (the AACR-NCI-EORTC October 2025 abstract B031, ESMO 2025, the November 2025 Fast Track announcement, the 2026 IPO prospectus, and the ESMO 2026 oral presentation of 24 October 2026, abstract 3715O). The platform validation story is industry-significant: if zolucatetide succeeds in Phase 3, it establishes that Helicon-style polymacrocyclic helical peptides can drug intracellular protein-protein interactions that resisted small-molecule chemistry for decades — a thesis that would justify the broader Parabilis pipeline targeting other previously intractable PPI targets in oncology.
History & Discovery
Zolucatetide originated at Fog Pharmaceuticals (FogPharma), founded in 2015 on technology licensed from the Harvard laboratory of Gregory Verdine — a chemical biologist who pioneered hydrocarbon-stapled α-helical peptides as a strategy for drugging intracellular protein-protein interactions. The lineage runs from the Verdine lab's 2012 report of a stapled peptide that bound β-catenin directly and blocked its coactivation of TCF (PNAS 2012, PMID 23071338) — published alongside a Dana-Farber group's stapled BCL9 helix targeting a different β-catenin partner (Sci Transl Med 2012, PMID 22914623) — through FogPharma's Helicon platform of multiply cross-linked helical peptides engineered for cytosolic accumulation, to FOG-001 itself, found through Helicon phage-display screening against β-catenin's TCF-binding interface. The company is now led by CEO Mathai Mammen, a former Johnson & Johnson R&D executive. The Phase 1/2 trial NCT05919264 opened in May 2023 across solid tumors with Wnt-pathway-activating mutations, with expansion cohorts in colorectal cancer, hepatocellular carcinoma, desmoid tumors, and castration-resistant prostate cancer (later adding FAP), plus combination cohorts. The desmoid signal emerged as the lead clinical opportunity through 2024–2025: desmoid tumors have ~85% CTNNB1-mutation prevalence, well-defined RECIST-evaluable disease, an established response benchmark (nirogacestat's 41% ORR in the DeFi trial), and an unmet need that produced the November 2023 FDA approval of nirogacestat as the first desmoid-specific drug. Conference disclosures at ESMO 2025 and AACR-NCI-EORTC in October 2025 (abstract B031) built the clinical story, and on November 12, 2025 the FDA granted Fast Track designation for desmoid tumors on data showing tumor reductions in all 10 evaluable desmoid patients at an August 2025 cut. Fog Pharmaceuticals rebranded as Parabilis Medicines in October 2024, unveiling an AI- and physics-based discovery platform alongside the new name, and on January 8, 2026 closed an oversubscribed $305M Series F financing to support zolucatetide development across multiple indications and advance the broader Helicon pipeline. Zolucatetide received FDA Orphan Drug Designation for desmoid tumors on March 11, 2026. On May 18, 2026 Regeneron signed a research collaboration to develop antibody-Helicon conjugates, paying $50M upfront and buying $75M of stock, with up to about $2.2B in milestones — a platform deal rather than a zolucatetide license. Parabilis filed its IPO registration on May 19, 2026 and priced on June 9, 2026 at $20 a share (Nasdaq: PBLS): the base deal of 33.5 million shares raised $670M gross, rising to $770.5M once the underwriters' over-allotment option was exercised. The prospectus disclosed the February 2026 desmoid data — tumor reductions in all 25 evaluable patients and a 74% (14/19) RECIST 1.1 ORR, in both GSI-naive and GSI-failed patients — and a registrational Phase 3 in desmoid tumors targeted for H1 2027. In June 2026 a New England Journal of Medicine letter reported a durable response in a patient with recurrent Wnt-mutant ameloblastoma — the first peer-reviewed report involving the drug, though as a single-patient letter rather than a trial publication. The programme reached its first real inflection in October 2026. On 24 October, at ESMO Congress 2026 in Madrid, Parabilis presented updated Phase 1/2 desmoid data as an oral presentation (abstract 3715O): 76 patients treated as of a 22 June 2026 cutoff, a 72.2% (13/18) objective response rate at a 32-week landmark among the 48 who started at 450 mg or above, and 100% disease control across all 46 response-evaluable patients in that cohort, with no progression. Treatment-related adverse events were predominantly low-grade — most often fatigue, alopecia and nausea — with no discontinuations attributed to them, and without the ovarian, high-grade gastrointestinal or skin toxicities associated with the γ-secretase inhibitor class. The same announcement disclosed that a three-arm randomized dose-optimization study had settled the regimen (450 mg weekly for four cycles, then 300 mg every two weeks) and that end-of-Phase-2 discussions with the FDA had produced alignment on that regimen, a placebo-controlled design and progression-free survival as the registrational endpoint. The Phase 3 trial has a name — PEDESTAL, for Phase 3 Evaluation of DESmoid Tumor Activity with zoLucatetide — a planned start in the first half of 2027 and expected topline results in 2029. The scientific significance extends beyond desmoid. Zolucatetide is the first molecule ever to clinically validate direct β-catenin:TCF inhibition — a target the field considered undruggable since the interaction's structural characterization in the 1990s. If the Phase 3 confirms the early ORR signal and the molecule progresses to approval, it establishes the Helicon class as a viable platform for drugging the large class of intracellular protein-protein interactions historically out of reach for both small molecules and conventional biologics.
How It Works
In many cancers — including desmoid tumors, most colon cancers, and some liver, endometrial, and prostate cancers — a switch called the Wnt pathway is stuck on. The final step in that pathway is when β-catenin binds to a partner protein called TCF, which then turns on cancer-driving genes. Zolucatetide is a designed helical peptide that physically blocks β-catenin from binding TCF — interrupting the cancer-driving signal at its central point. It's the first drug to ever directly hit this target, which the field considered impossible to drug for thirty years.
The Wnt pathway is a fundamental cellular signaling cascade with central roles in development, tissue regeneration, and oncogenesis. In the canonical pathway, β-catenin is normally targeted for proteasomal degradation by a destruction complex (APC, Axin, GSK3β, CK1). Wnt ligand engagement of Frizzled/LRP5/6 receptors inhibits the destruction complex, allowing β-catenin to accumulate, translocate to the nucleus, and bind TCF/LEF family transcription factors at Wnt-responsive promoters — driving transcription of MYC, CCND1, AXIN2, LGR5, and other targets that promote proliferation and survival. Loss-of-function APC mutations (familial adenomatous polyposis and most sporadic colorectal cancers) and gain-of-function CTNNB1 mutations (T41A, S45F, S45P — common in desmoid tumors, hepatocellular carcinoma, endometrial cancer) all converge on stabilized nuclear β-catenin. The downstream β-catenin:TCF protein-protein interaction is therefore the central transcriptional node where Wnt-pathway dysregulation drives oncogenesis. The interface itself is ~4,800 Ų of flat, hydrophobic surface — incompatible with conventional small-molecule drug discovery, which has historically required deeper pockets to achieve nanomolar affinity and selectivity. Zolucatetide is a polymacrocyclic α-helical peptide (Helicon class) engineered to bind β-catenin at the TCF-binding face; its helix is braced by an all-hydrocarbon staple, a carbamate bridge, and a side-chain lactam. Parabilis has not published binding or potency data for zolucatetide in a peer-reviewed paper, and figures circulating on research-chemical vendor listings are not a usable source. The mechanism is direct: by occupying the TCF interaction surface, zolucatetide displaces TCF from β-catenin and prevents formation of the transcriptionally active β-catenin:TCF complex, shutting down Wnt-pathway transcriptional output downstream of stabilized β-catenin — regardless of whether the upstream driver is APC loss or CTNNB1 activation. This positions zolucatetide as a mechanistically unified therapy across the diverse spectrum of Wnt-pathway-activated cancers, in contrast to upstream-pathway agents whose effects depend on the specific level of pathway dysregulation.
Evidence Snapshot
Human Clinical Evidence
Phase 1/2 NCT05919264 (n=619 estimated, recruiting) across desmoid, CRC, HCC, prostate, FAP, and broader Wnt-pathway-activated cohorts, with combination cohorts. At the August 2025 data cut (12 desmoid patients treated), all 10 evaluable patients had tumor reductions and the ORR was 80% among those with more than one post-baseline scan. The ESMO 2026 presentation (22 June 2026 cut) reported 76 desmoid patients treated across all dose levels, a 72.2% (13/18) RECIST 1.1 ORR at a 32-week landmark among those starting at 450 mg or above, 100% disease control across all 46 response-evaluable patients in that cohort, no progression, and a median 4.7 months on treatment, with activity in both GSI-naive and GSI-failed patients. The earlier February 2026 IPO cut reported 38 patients treated and a 74% (14/19) ORR. Outside desmoid: one HCC partial response lasting nine months, ctDNA reductions in some CRC patients, polyp-burden improvement in two FAP patients, and a durable response in one ameloblastoma patient (NEJM 2026 letter, PMID 42235020). No peer-reviewed trial publication yet; an ESMO 2026 oral presentation is scheduled.
Animal / Preclinical
Moderate. Parabilis's preclinical zolucatetide data have been presented at conferences rather than in peer-reviewed papers. The underlying approach — stabilized helical peptides that directly block β-catenin's transcriptional partners — is supported by academic work: Verdine's lab reported a hydrocarbon-stapled peptide that binds β-catenin and blocks TCF-driven transcription (PNAS 2012, PMID 23071338), and a separate Dana-Farber group showed a stapled BCL9 helix (SAH-BCL9) suppressed Wnt transcription and tumor growth in Colo320 colorectal and INA-6 myeloma xenografts (Sci Transl Med 2012, PMID 22914623).
Mechanistic Rationale
Strong. The Wnt-pathway central role in Wnt-mutant cancers is rigorously established. Direct β-catenin:TCF inhibition has been the rational target for decades; what zolucatetide adds is the first molecule that can actually engage it in cells and humans.
Research Gaps & Open Questions
What the current literature has not yet settled about Zolucatetide:
- 01Peer-reviewed trial publication — the only PubMed-indexed zolucatetide paper is a single-patient NEJM letter (ameloblastoma); desmoid efficacy and safety data come from conference abstracts, press releases, and IPO filings.
- 02Durability of response and median PFS — the disclosed data still carry no time-to-event endpoints, and median time on treatment at the June 2026 cut was only 4.7 months. Progression-free survival is the primary endpoint of PEDESTAL, so the first real answer arrives with that trial's 2029 topline.
- 03Head-to-head comparison versus nirogacestat or varegacestat — no randomized comparison exists, and both γ-secretase inhibitors are oral while zolucatetide is IV.
- 04Detailed safety data — the ESMO presentation named the most common treatment-related adverse events (fatigue, alopecia, nausea) and reported no discontinuations because of them, but grade 3 laboratory abnormalities, infusion-related effects and the exposure-adjusted adverse-event profile have not been reported in any format, peer-reviewed or otherwise.
- 05Performance in non-desmoid cohorts — CRC, HCC, prostate, and other Wnt-mutant tumor data have been disclosed only as isolated responses (one HCC partial response, CRC ctDNA reductions), not at the same maturity as desmoid.
- 06Combination signal — combination cohorts (mFOLFOX/bevacizumab, nivolumab, FTD/TPI/bevacizumab) are early; mature efficacy data pending.
- 07Long-term safety — Phase 1/2 exposure timelines have not been reported in detail; chronic dosing safety is the question Phase 3 must address.
Forms & Administration
Intravenous infusion on continuous 28-day cycles per NCT05919264 protocol. Investigational — not commercially available. The Phase 1/2 protocol includes a subcutaneous arm, but disclosed clinical activity is IV. Oncology specialty supervision required for any trial participation.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
A regimen has now been selected for registrational development and agreed with the FDA: 450 mg weekly as an induction dose for four cycles, followed by 300 mg every two weeks for long-term maintenance. This emerged from a three-arm randomized dose-optimization portion of NCT05919264, and it is the regimen the Phase 3 PEDESTAL trial is designed around. Earlier dose-escalation cohorts ranged higher — two patients began at 900 mg — but averaged 400 to 500 mg over the first four months.
Frequency
Intravenous infusion on continuous 28-day cycles. The selected regimen is weekly during induction, then every two weeks during maintenance.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
28-day continuous cycles per the Phase 1/2 protocol; induction runs for four cycles before the switch to every-two-week maintenance.
Protocol Notes
Zolucatetide is in active Phase 1/2 development and is not commercially available. Eligible patients with desmoid tumors or other Wnt-pathway-activated cancers should discuss NCT05919264 enrollment with their oncologist.
Zolucatetide is investigational and Phase 1/2 stage. Specialty oncology supervision is required for any clinical trial participation. The molecule is not legitimately available outside registered clinical trials.
Timeline of Effects
Onset
Standard solid-tumor response assessment timeline — initial RECIST evaluation typically at 6–9 weeks (2–3 cycles). Desmoid tumor responses, by historical experience with nirogacestat and other Wnt-pathway-active agents, can take longer to declare than typical solid-tumor responses given desmoid's slower growth kinetics.
Peak Effect
Per the ESMO 2026 presentation (22 June 2026 data cut): a 72.2% (13/18) RECIST 1.1 objective response rate at a 32-week landmark and 100% disease control across 46 response-evaluable patients, with no progression reported. Median time on treatment was 4.7 months (range 0.5–22.3), so these are interim figures on short exposure. Durability of response and median progression-free survival remain pending peer-reviewed publication and the Phase 3 readout; PFS is the primary endpoint of PEDESTAL, which is expected to report topline in 2029.
After Discontinuation
Off-treatment durability data not yet disclosed. Desmoid tumors historically show variable behavior after treatment discontinuation across Wnt-pathway-active therapies.
Common Questions
How is zolucatetide different from nirogacestat (Ogsiveo) for desmoid tumors?
Nirogacestat is an oral small-molecule γ-secretase inhibitor that affects the Notch pathway, with downstream effects on Wnt signaling — its desmoid activity is mechanistically indirect. Zolucatetide is an IV-administered Helicon helical peptide that binds β-catenin directly at the TCF interaction interface, blocking the central transcriptional driver of desmoid tumor biology directly. The DeFi pivotal trial of nirogacestat reported 41% ORR vs 8% placebo (45.7% with long-term follow-up), and a second γ-secretase inhibitor, varegacestat, reported 56% vs 9% in its Phase 3. At ESMO 2026, Parabilis reported a 72.2% (13/18) ORR for zolucatetide at a 32-week landmark and 100% disease control across 46 response-evaluable Phase 1/2 desmoid patients, including patients who progressed on prior GSI therapy. There is also a tolerability difference worth knowing about: the γ-secretase inhibitors carry ovarian toxicity — in the DeFi trial, 27 of 36 women of childbearing potential had adverse events consistent with ovarian dysfunction — while Parabilis reports none with zolucatetide. Desmoid tumors skew young and female, so that distinction matters clinically, though it rests on cross-trial comparison rather than a randomized head-to-head. The numerical comparison favors zolucatetide, but it is not a head-to-head trial — the patient populations, trial designs, and evidence maturity are different, and zolucatetide requires IV infusion while both GSIs are oral pills.
What is the Helicon platform?
Helicon is Parabilis Medicines' (formerly Fog Pharmaceuticals) platform for designing stabilized α-helical peptides as drugs against intracellular protein-protein interactions. Classic 'stapled' peptides use a single all-hydrocarbon bridge (typically i,i+4 or i,i+7) to lock a helix. Helicon peptides like zolucatetide go further, combining a hydrocarbon staple with additional cross-links (in zolucatetide's case a carbamate bridge and a side-chain lactam) and non-natural amino acids to enforce helicity, reduce solvent-exposed amide hydrogen-bond donors, and enable cytosolic accumulation sufficient to engage intracellular targets. Parabilis was founded in 2015 on technology licensed from the Harvard laboratory of Gregory Verdine, a pioneer of stapled-peptide chemistry, whose group reported a hydrocarbon-stapled peptide that directly targets β-catenin and blocks its coactivation of TCF in 2012 (PMID 23071338). The same platform has since been applied to other intracellular targets such as E3 ubiquitin ligases (PMID 37914719).
Why was β-catenin:TCF considered undruggable?
The β-catenin:TCF binding interface is large (~4,800 Ų), flat, and hydrophobic — the opposite of the small, deep, polar pockets that conventional small molecules bind effectively. Drug-discovery efforts for three decades have targeted upstream Wnt-pathway nodes (porcupine, tankyrase, Wnt secretion) or downstream consequences (Notch crosstalk via γ-secretase inhibition) precisely because the central β-catenin:TCF interaction was thought inaccessible to drugs of conventional size and properties. Helical peptides of the Helicon class are large enough to make extensive contact across an interface like this while remaining cell-penetrant — which is the central platform thesis behind zolucatetide.
Is zolucatetide oral?
No. Zolucatetide is administered intravenously on continuous 28-day cycles. The Phase 1/2 protocol (NCT05919264) lists both IV and SC arms, but disclosed clinical activity has been IV. Oral bioavailability of large modified helical peptides remains an open engineering question that the Helicon platform has not solved as of zolucatetide's current development stage.
What other tumors is zolucatetide being tested in?
Beyond desmoid tumors, Parabilis has reported early signals in other Wnt-driven diseases. Its IPO prospectus described a confirmed partial response lasting nine months in a patient with CTNNB1-mutant hepatocellular carcinoma, disease stabilization and falling circulating tumor DNA in a subset of colorectal cancer patients, and marked improvement in duodenal polyp burden in two patients with familial adenomatous polyposis (FAP). A 2026 New England Journal of Medicine letter described a durable clinical and radiologic response in a patient with recurrent, Wnt-pathway-mutant ameloblastoma, a rare jaw tumor. Parabilis is opening a dedicated FAP cohort and expects more data in adamantinomatous craniopharyngioma, a Wnt-driven childhood brain tumor, in 2027. All of these are single cases or small cohorts, not trial results.
Is this approved or available?
No. Zolucatetide is investigational, in Phase 1/2 (NCT05919264). Legitimate access is enrollment in the registered Phase 1/2 trial. FDA Fast Track (November 2025) and Orphan Drug (March 2026) designations for desmoid tumors do not constitute approval. Parabilis completed end-of-Phase-2 discussions with the FDA and announced alignment in October 2026 on the dose, a placebo-controlled design and progression-free survival as the primary endpoint. The resulting registrational trial, PEDESTAL, is planned to begin in the first half of 2027 and to report topline results in 2029, funded by the June 2026 IPO. One practical note for anyone searching: ClinicalTrials.gov returns nothing for the name zolucatetide — the registry record still uses the development code FOG-001. Any non-trial source claiming to sell zolucatetide should be presumed unverified material — large modified helical peptides cannot be synthesized by research-chemical operations.
Who Zolucatetide Is NOT For
- •Oncology trial enrollment only — outside NCT05919264, no legitimate access exists.
- •Pregnancy and breastfeeding — investigational oncology agent with no human reproductive data.
- •Severe baseline hepatic or renal impairment — Phase 1/2 exclusion criteria pending publication.
- •Known hypersensitivity to Helicon-class peptides — no specific allergen profile published but standard biologic-class precaution.
Drug & Supplement Interactions
No established drug interaction profile because zolucatetide is investigational. The Phase 1/2 includes combination cohorts with mFOLFOX-6 + bevacizumab (CRC), nivolumab (multi-tumor), and trifluridine/tipiracil + bevacizumab (CRC), indicating manageable combinability with major cytotoxic and immunotherapy regimens. Specific drug-drug interaction analyses will be characterized in published trial results.
Safety Profile
Common Side Effects
Cautions
- • Investigational — Phase 1/2 stage
- • Oncology drug — managed under specialty oncology care only
- • Limited number of evaluable patients in disclosed efficacy datasets
- • Requires intravenous infusion, unlike the oral γ-secretase inhibitors used for desmoid tumors
- • Safety data remain conference-presented rather than peer-reviewed, and the exposure-adjusted adverse-event profile has not been published
What We Don't Know
Long-term safety and tolerability, durability of response, comparative profile versus nirogacestat and varegacestat, and performance in a randomized Phase 3 setting are all pending. Median time on treatment at the June 2026 cut was 4.7 months, so chronic-exposure safety for a disease usually treated for years is essentially uncharacterized. One difference from the γ-secretase inhibitor class is already visible, though it comes from cross-trial comparison rather than a head-to-head study: Parabilis reports no ovarian toxicity and no high-grade gastrointestinal or skin toxicity, whereas the pivotal nirogacestat trial reported adverse events consistent with ovarian dysfunction in 27 of 36 women of childbearing potential.
Legal Status
United States
Not FDA-approved. Investigational, Phase 1/2 stage. For desmoid tumors the FDA granted Fast Track designation (November 12, 2025), which allows more frequent FDA interaction and rolling review, and Orphan Drug Designation (March 11, 2026), which brings tax credits, fee waivers, and seven years of market exclusivity if approved — neither is an approval. Following end-of-Phase-2 discussions the FDA has aligned with Parabilis on dose, a placebo-controlled design and progression-free survival as the registrational endpoint; the resulting Phase 3 trial, PEDESTAL, is planned for the first half of 2027 with topline results expected in 2029. FDA feedback of this kind is not binding and does not guarantee approval. Legitimate access is limited to enrollment in NCT05919264.
International
No regulatory approval anywhere. Investigational across all major regulators.
Sports & Competition
Zolucatetide is not named on the 2026 or 2027 WADA Prohibited List. As an investigational drug not approved by any government regulatory health authority, it technically falls under WADA's S0 'Non-approved substances' category, which prohibits such substances at all times, although an oncology drug has no plausible performance use.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Zolucatetide is just a classic single-staple peptide.
Reality
Partly true. Zolucatetide does contain an all-hydrocarbon staple of the classic kind, but that is only one of three cross-links — its WHO INN chemical name also describes a carbamate bridge and a side-chain lactam, plus several non-natural amino acids. The Helicon platform is the next generation of stabilized helical peptide engineering, and the extra architecture matters for cell penetration and target engagement. (SAH-BCL9, often cited as its ancestor, came from a separate Dana-Farber group and targets β-catenin's BCL9 interface rather than TCF.)
Myth
Because zolucatetide directly hits an undruggable target, it will cure desmoid and Wnt-driven cancers.
Reality
The 74% RECIST ORR figure is striking, but it comes from 14 of 19 patients in an open-label Phase 1/2, is not yet peer-reviewed, and does not yet include mature time-to-event endpoints (PFS, DOR, OS). Desmoid tumors also have substantial heterogeneity: roughly 25–38% undergo spontaneous regression during active surveillance, which is why active surveillance is the recommended first-line strategy. That makes a 100% disease control rate harder to interpret than it looks, and it is why the placebo arm in PEDESTAL matters. Phase 3 randomized data is the test that will confirm or reframe these early signals.
Myth
If it works in desmoid, it'll work in colorectal cancer where most patients have APC mutations.
Reality
Mechanistically, blocking β-catenin:TCF should work across APC-loss and CTNNB1-mutant cancers — that's the appeal. But translation has been the hard part. Desmoid tumors are mesenchymal, single-mutation-driven, slow-growing, and biologically simpler than the heavily mutated, microenvironmentally complex colorectal cancers. Most targeted-therapy programs in CRC underperform expectations set by clean single-driver indications. Zolucatetide's CRC data has not been disclosed at the same maturity as desmoid, and the cross-indication translation should not be assumed.
Myth
Zolucatetide is available outside the trial through compounding or research-chemical channels.
Reality
Zolucatetide is a large modified helical peptide (C102H134N18O25S2, MW 2,076 Da) with three cross-links, several non-natural amino acids, and tightly controlled chemistry. It cannot be made by research-chemical operations, and no compounding-pharmacy supply exists. Any product sold outside Parabilis's registered clinical trials claiming to be zolucatetide is unverified and not authentic material.
Published Research
23 studiesMolecular Mechanisms Underlying Progression and Spontaneous Regression in Desmoid Tumors.
RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial.
Targeting of Wnt-β-Catenin Pathway in Recurrent Ameloblastoma.
Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial.
Recognition and reprogramming of E3 ubiquitin ligase surfaces by α-helical peptides.
Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.
De novo mapping of α-helix recognition sites on protein surfaces using unbiased libraries.
Inhibition of oncogenic Wnt signaling through direct targeting of β-catenin.
Grossmann TN … Verdine GL, PNAS 2012 (Harvard). Reports a hydrocarbon-stapled peptide that binds β-catenin directly and blocks its coactivation of TCF — the academic proof of concept for the direct β-catenin approach that Verdine's company, Fog Pharmaceuticals / Parabilis Medicines, later took to the clinic with zolucatetide.
Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling.
NCT05919264 — A Phase 1/2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1/2 open-label study (estimated n=619, recruiting, sponsor Parabilis Medicines) of zolucatetide (FOG-001) in solid tumors with Wnt-pathway activating mutations, spanning CRC, HCC, desmoid, castration-resistant prostate cancer, FAP, and other WPAM-tumor cohorts plus combination cohorts with mFOLFOX-6+bevacizumab, nivolumab, and trifluridine/tipiracil+bevacizumab. Primary endpoints: TEAE/DLT (escalation), ORR per RECIST 1.1 (expansion), DCR, PSA30 for prostate.
Parabilis Medicines S-1 Registration Statement (May 19, 2026)
Parabilis Medicines IPO S-1 disclosure (May 19, 2026) including the zolucatetide desmoid efficacy summary: tumor reductions in 100% of evaluable patients, 74% RECIST 1.1 ORR in patients with at least two post-baseline scans, activity in both GSI-naive and GSI-failed patients regardless of CTNNB1/APC mutation status. Proceeds earmarked for H1 2027 registrational Phase 3 in desmoid.
Parabilis Medicines final IPO prospectus (Form 424B4, June 2026)
Final prospectus for the 33.5-million-share IPO at $20 (Nasdaq: PBLS). As of February 16, 2026: 38 desmoid patients treated, all 25 response-evaluable patients with tumor reductions, 74% (14/19) RECIST 1.1 ORR; a nine-month partial response in CTNNB1-mutant HCC, ctDNA reductions in CRC, and polyp-burden improvement in two FAP patients. Phase 3 in desmoid planned for H1 2027.
Parabilis Medicines Receives FDA Fast Track Designation for FOG-001 for the Treatment of Desmoid Tumors (November 12, 2025)
Parabilis Medicines — Zolucatetide receives FDA Orphan Drug Designation for desmoid tumors (March 11, 2026)
Parabilis Medicines announces oversubscribed $305 million financing (January 8, 2026)
AACR-NCI-EORTC October 2025 Abstract B031 — Phase 1/2 preliminary safety and efficacy of FOG-001 in Wnt-pathway-activated solid tumors
BioPharma Dive — Parabilis IPO and the Helicon peptide approach to undruggable targets
BioPharma Dive — Parabilis prices IPO at $20 per share, raising $670M (June 9, 2026)
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates (August 13, 2026)
FierceBiotech — Parabilis Medicines rockets ahead with $305M fundraise to upend status quo
FDA approval of Ogsiveo (nirogacestat) — first approved therapy for desmoid tumors (November 27, 2023)
Immunome announces FDA acceptance of NDA for varegacestat for adults with desmoid tumors (July 8, 2026)
Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide in Patients with Desmoid Tumors (ESMO Congress 2026, abstract 3715O, October 24, 2026)
The current zolucatetide desmoid dataset. As of a 22 June 2026 cutoff, 76 patients had been enrolled and treated; among the 48 starting at 450 mg or above, 46 were response-evaluable and 18 had reached a 32-week landmark, giving a 72.2% (13/18) RECIST 1.1 objective response rate and a 100% disease control rate across all 46, with no progression and a median 4.7 months on treatment. Treatment-related adverse events were predominantly low-grade (most commonly fatigue, alopecia and nausea) with no discontinuations attributed to them. The release also announced the selected Phase 3 regimen (450 mg weekly induction for four cycles, then 300 mg every two weeks) and FDA alignment on PEDESTAL. Company-issued, not peer-reviewed.
Quick Facts
- Class
- Helicon Stabilized Helical Peptide
- Tier
- C
- Evidence
- Moderate
- Safety
- Limited Data
- Updated
- Nov 2026
- Citations
- 23PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.